Lack of long-term adverse adrenal effects from inhaled triamcinolone: Lung Health Study II

Michael S. Eichenhorn, Robert A. Wise, Thelma C. Madhok, Lynn B Gerald, William C. Bailey, Donald P. Tashkin, Paul D. Scanlon, John E. Connett

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Study objectives: Inhaled corticosteroids (ICS) are widely used in the treatment of COPD. One of the potential adverse effects of their use is the development of adrenal suppression. Our study aimed to determine the effects of ICS on adrenal function over 3 years of use in patients with COPD. Methods: Two hundred twenty-one subjects were recruited from the 1,116 patients already enrolled in Lung Health Study II and were randomized to receive either triamcinolone, 1,200 μg, or placebo daily. Basal cortisol levels and cortisol levels at 30 min and 60 min following cosyntropin injection were measured at study entry and after 1 year and 3 years of participation. Results: Basal cortisol levels in the placebo group were higher than in those receiving active drug at all time points and rose through the study period. There was no suppression of cortisol levels after cosyntropin stimulation at any study point in any subgroup. Conclusion: Use of inhaled triamcinolone, 1,200 μg/d, over 3 years does not suppress baseline adrenal function or diminish adrenal responsiveness to cosyntropin stimulation.

Original languageEnglish (US)
Pages (from-to)57-62
Number of pages6
JournalChest
Volume124
Issue number1
DOIs
StatePublished - Jul 1 2003
Externally publishedYes

Fingerprint

Triamcinolone
Cosyntropin
Hydrocortisone
Lung
Health
Chronic Obstructive Pulmonary Disease
Adrenal Cortex Hormones
Placebos
Injections
Long Term Adverse Effects
Pharmaceutical Preparations
Therapeutics

Keywords

  • Adrenal function
  • COPD
  • Inhaled corticosteroids
  • Stimulated cortisol response

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Eichenhorn, M. S., Wise, R. A., Madhok, T. C., Gerald, L. B., Bailey, W. C., Tashkin, D. P., ... Connett, J. E. (2003). Lack of long-term adverse adrenal effects from inhaled triamcinolone: Lung Health Study II. Chest, 124(1), 57-62. https://doi.org/10.1378/chest.124.1.57

Lack of long-term adverse adrenal effects from inhaled triamcinolone : Lung Health Study II. / Eichenhorn, Michael S.; Wise, Robert A.; Madhok, Thelma C.; Gerald, Lynn B; Bailey, William C.; Tashkin, Donald P.; Scanlon, Paul D.; Connett, John E.

In: Chest, Vol. 124, No. 1, 01.07.2003, p. 57-62.

Research output: Contribution to journalArticle

Eichenhorn, MS, Wise, RA, Madhok, TC, Gerald, LB, Bailey, WC, Tashkin, DP, Scanlon, PD & Connett, JE 2003, 'Lack of long-term adverse adrenal effects from inhaled triamcinolone: Lung Health Study II', Chest, vol. 124, no. 1, pp. 57-62. https://doi.org/10.1378/chest.124.1.57
Eichenhorn, Michael S. ; Wise, Robert A. ; Madhok, Thelma C. ; Gerald, Lynn B ; Bailey, William C. ; Tashkin, Donald P. ; Scanlon, Paul D. ; Connett, John E. / Lack of long-term adverse adrenal effects from inhaled triamcinolone : Lung Health Study II. In: Chest. 2003 ; Vol. 124, No. 1. pp. 57-62.
@article{ccbe23ea2f3a4deab7ca2de50cc32ebe,
title = "Lack of long-term adverse adrenal effects from inhaled triamcinolone: Lung Health Study II",
abstract = "Study objectives: Inhaled corticosteroids (ICS) are widely used in the treatment of COPD. One of the potential adverse effects of their use is the development of adrenal suppression. Our study aimed to determine the effects of ICS on adrenal function over 3 years of use in patients with COPD. Methods: Two hundred twenty-one subjects were recruited from the 1,116 patients already enrolled in Lung Health Study II and were randomized to receive either triamcinolone, 1,200 μg, or placebo daily. Basal cortisol levels and cortisol levels at 30 min and 60 min following cosyntropin injection were measured at study entry and after 1 year and 3 years of participation. Results: Basal cortisol levels in the placebo group were higher than in those receiving active drug at all time points and rose through the study period. There was no suppression of cortisol levels after cosyntropin stimulation at any study point in any subgroup. Conclusion: Use of inhaled triamcinolone, 1,200 μg/d, over 3 years does not suppress baseline adrenal function or diminish adrenal responsiveness to cosyntropin stimulation.",
keywords = "Adrenal function, COPD, Inhaled corticosteroids, Stimulated cortisol response",
author = "Eichenhorn, {Michael S.} and Wise, {Robert A.} and Madhok, {Thelma C.} and Gerald, {Lynn B} and Bailey, {William C.} and Tashkin, {Donald P.} and Scanlon, {Paul D.} and Connett, {John E.}",
year = "2003",
month = "7",
day = "1",
doi = "10.1378/chest.124.1.57",
language = "English (US)",
volume = "124",
pages = "57--62",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "1",

}

TY - JOUR

T1 - Lack of long-term adverse adrenal effects from inhaled triamcinolone

T2 - Lung Health Study II

AU - Eichenhorn, Michael S.

AU - Wise, Robert A.

AU - Madhok, Thelma C.

AU - Gerald, Lynn B

AU - Bailey, William C.

AU - Tashkin, Donald P.

AU - Scanlon, Paul D.

AU - Connett, John E.

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Study objectives: Inhaled corticosteroids (ICS) are widely used in the treatment of COPD. One of the potential adverse effects of their use is the development of adrenal suppression. Our study aimed to determine the effects of ICS on adrenal function over 3 years of use in patients with COPD. Methods: Two hundred twenty-one subjects were recruited from the 1,116 patients already enrolled in Lung Health Study II and were randomized to receive either triamcinolone, 1,200 μg, or placebo daily. Basal cortisol levels and cortisol levels at 30 min and 60 min following cosyntropin injection were measured at study entry and after 1 year and 3 years of participation. Results: Basal cortisol levels in the placebo group were higher than in those receiving active drug at all time points and rose through the study period. There was no suppression of cortisol levels after cosyntropin stimulation at any study point in any subgroup. Conclusion: Use of inhaled triamcinolone, 1,200 μg/d, over 3 years does not suppress baseline adrenal function or diminish adrenal responsiveness to cosyntropin stimulation.

AB - Study objectives: Inhaled corticosteroids (ICS) are widely used in the treatment of COPD. One of the potential adverse effects of their use is the development of adrenal suppression. Our study aimed to determine the effects of ICS on adrenal function over 3 years of use in patients with COPD. Methods: Two hundred twenty-one subjects were recruited from the 1,116 patients already enrolled in Lung Health Study II and were randomized to receive either triamcinolone, 1,200 μg, or placebo daily. Basal cortisol levels and cortisol levels at 30 min and 60 min following cosyntropin injection were measured at study entry and after 1 year and 3 years of participation. Results: Basal cortisol levels in the placebo group were higher than in those receiving active drug at all time points and rose through the study period. There was no suppression of cortisol levels after cosyntropin stimulation at any study point in any subgroup. Conclusion: Use of inhaled triamcinolone, 1,200 μg/d, over 3 years does not suppress baseline adrenal function or diminish adrenal responsiveness to cosyntropin stimulation.

KW - Adrenal function

KW - COPD

KW - Inhaled corticosteroids

KW - Stimulated cortisol response

UR - http://www.scopus.com/inward/record.url?scp=0038498561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038498561&partnerID=8YFLogxK

U2 - 10.1378/chest.124.1.57

DO - 10.1378/chest.124.1.57

M3 - Article

C2 - 12853502

AN - SCOPUS:0038498561

VL - 124

SP - 57

EP - 62

JO - Chest

JF - Chest

SN - 0012-3692

IS - 1

ER -